{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:10:28Z","timestamp":1653509428525},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1994,9]]},"abstract":"<jats:sec><jats:title>PURPOSE AND METHODS<\/jats:title><jats:p> Thirty-nine consecutive children (age, 2 to 11 years) with nonlymphoblastic (NL) lymphomas were treated uniformly with chemotherapy based on the LNH-II-85 protocol. The protocol consisted of a remission-induction phase that lasted 30 days and started with cyclophosphamide (CTX) 1.2 g\/m2 on day 1, followed by vincristine (VCR) 1.5 mg\/m2 on days 3, 10, 17, and 24, daunomycin (DAUNO) 60 mg\/m2 on days 12 and 13, and prednisone 40 mg\/m2\/d for 30 days. If a complete remission was achieved, an intensification regimen was given that consisted of eight courses of teniposide (VM-26) 165 mg\/m2 plus cytarabine (ARA-C) 300 mg\/m2 every 4 days according to bone marrow tolerance. A continuation phase was subsequently started, with alternating courses of thioguanine (6-TG) 300 mg\/m2\/d for 4 days plus CTX 1.2 g\/m2 on day 5; hydroxyurea 2.5 g\/m2\/d for 4 days plus DAUNO 45 mg\/m2 on day 5; VCR 1.5 mg\/m2 plus methotrexate (MTX) 120 mg\/m2 (24 hours apart); mercaptopurine (6-MP) 500 mg\/m2\/d for 4 days plus MTX 40 mg\/m2; and VM-26 plus ARA-C for 3 courses (4 days apart), by the end of 48 weeks. CNS prophylaxis consisted of intrathecal administration of MTX, ARA-C, and dexamethasone according to age, administered three times during remission induction and every 6 weeks afterwards. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> By the end of the analysis in July 1991, 38 of 39 patients had attained a complete remission and 36 were event-free survivors. Two failures that occurred after completion of therapy were second malignancies (acute lymphocytic leukemia and acute nonlymphocytic leukemia). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> These results are significantly better than those obtained with less intensive former regimens performed in our institution before the availability of VM-26. The favorable impact of an intense consolidation phase with VM-26 is remarkably exemplified by three additional patients not included in this study whose families withdrew them from therapy after the intensification phase, all three of whom have been in remission. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.1994.12.9.1963","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T12:46:52Z","timestamp":1487854012000},"page":"1963-1968","source":"Crossref","is-referenced-by-count":3,"title":["Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood."],"prefix":"10.1200","volume":"12","author":[{"given":"P T","family":"Maluf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Odone Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L M","family":"Cristofani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Britto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M T","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J G","family":"Maksoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Manissadjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1994.12.9.1963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:53:52Z","timestamp":1653508432000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1994.12.9.1963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,9]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1994,9]]}},"alternative-id":["10.1200\/JCO.1994.12.9.1963"],"URL":"https:\/\/doi.org\/10.1200\/jco.1994.12.9.1963","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,9]]}}}